갑상선 질환의 방사성요오드 치료와 이차암 발생

키워드

참고문헌 (66)

1. Hong JY, "Association of exposure to diagnostic low-dose ionizing radiation with risk of cancer among youths in South Korea", JAMA Netw Open, 2(9), pp.e1910584~ (2019)
2. Guiu-Souto J, "Adaptive biokinetic modelling of iodine-131 in thyroid cancer treatments : implications on individualised internal dosimetry", J Radiol Prot, 38(4), pp.1501~1511 (2018)
3. Kolbert KS, "Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software", J Nucl Med, 48(1), pp.143~149 (2007)
4. Clement SC, "Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma--a systematic review", Cancer Treat Rev, 41(10), pp.925~934 (2015)
5. Silva-Vieira M, "Second primary cancer in patients with differentiated thyroid cancer : does radioiodine play a role?", Thyroid, 27(8), pp.1068~1076 (2017)
6. Brown AP, "The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer", J Clin Endocrinol Metab, 93(2), pp.504~515 (2008)
7. Hirsch D, "Incidence of nonthyroidal primary malignancy and the association with(131)I treatment in patients with differentiated thyroid cancer", Thyroid, 26(8), pp.1110~1116 (2016)
8. Rubino C, "Second primary malignancies in thyroid cancer patients", Br J Cancer, 89(9), pp.1638~1644 (2003)
9. Sawka AM, "Second primary malignancy risk after radioactive iodine treatment for thyroid cancer : a systematic review and meta-analysis", Thyroid, 19(5), pp.451~457 (2009)
10. Hakala TT, "Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer", Int J Clin Oncol, 21(2), pp.231~239 (2016)
11. Khang AR, "The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative(131)I dose over 37 GBq", Clin Endocrinol(Oxf), 83(1), pp.117~123 (2015)
12. Teng CJ, "Use of radioactive iodine for thyroid cancer and risk of second primary malignancy : a nationwide population-based study", J Natl Cancer Inst, 108(2), pp.djv314~ (2016)
13. Yu CY, "A systematic review and meta-analysis of subsequent malignant neoplasm risk after radioactive iodine treatment of thyroid cancer", Thyroid, 28(12), pp.1662~1673 (2018)
14. Pasqual E, "Association between radioactive iodine treatment for pediatric and young adulthood differentiated thyroid cancer and risk of second primary malignancies", J Clin Oncol, 40(13), pp.1439~1449 (2022)
15. Molenaar RJ, "Risk of hematologic malignancies after radioiodine treatment of well-differentiated thyroid cancer", J Clin Oncol, 36(18), pp.1831~1839 (2018)
16. Metso S, "Increased cancer incidence after radioiodine treatment for hyperthyroidism", Cancer, 109(10), pp.1972~1979 (2007)
17. Kitahara CM, "Association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism", JAMA Intern Med, 179(8), pp.1034~1042 (2019)
18. Gronich N, "Cancer risk after radioactive iodine treatment for hyperthyroidism : a cohort study", Thyroid, 30(2), pp.243~250 (2020)
19. Shim SR, "Cancer risk after radioactive iodine treatment for hyperthyroidism : a systematic review and meta-analysis", JAMA Netw Open, 4(9), pp.e2125072~ (2021)
20. Preston DL, "Solid cancer incidence in atomic bomb survivors : 1958-1998", Radiat Res, 168(1), pp.1~64 (2007)
21. Preston DL, "Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987", Radiat Res, 137(2 Suppl), pp.S68~97 (1994)
22. Furukawa K, "Long-term trend of thyroid cancer risk among Japanese atomic-bomb survivors : 60 years after exposure", Int J Cancer, 132(5), pp.1222~1226 (2013)
23. Grant EJ, "Solid cancer incidence among the life span study of atomic bomb survivors : 1958-2009", Radiat Res, 187(5), pp.513~537 (2017)
24. Muirhead CR, "Mortality and cancer incidence following occupational radiation exposure : third analysis of the National Registry for Radiation Workers", Br J Cancer, 100(1), pp.206~212 (2009)
25. Radivoyevitch T, "Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation", Leukemia, 30(2), pp.285~294 (2016)
26. Luster M, "Guidelines for radioiodine therapy of differentiated thyroid cancer", Eur J Nucl Med Mol Imaging, 35(10), pp.1941~1959 (2008)
27. Pacini F, "2022 ETA Consensus Statement : what are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?", Eur Thyroid J, 11(1), pp.e210046~ (2022)
28. Tuttle RM, "Controversies, consensus, and collaboration in the use of(131)I therapy in differentiated thyroid cancer : a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association", Thyroid, 29(4), pp.461~470 (2019)
29. Haugen BR, "2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer : the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer", Thyroid, 26(1), pp.1~133 (2016)
30. Luster M, "European perspective on 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer : proceedings of an Interactive International Symposium", Thyroid, 29(1), pp.7~26 (2019)
31. James DL, "Radioiodine remnant ablation for differentiated thyroid cancer : a systematic review and meta-analysis", JAMA Otolaryngol Head Neck Surg, 147(6), pp.544~552 (2021)
32. Hong CM, "Incidence rate and factors associated with the development of secondary cancers after radioiodine therapy in differentiated thyroid cancer : a multicenter retrospective study", Eur J Nucl Med Mol Imaging, 49(5), pp.1661~1670 (2022)
33. Ruel E, "Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer", J Clin Endocrinol Metab, 100(4), pp.1529~1536 (2015)
34. Hawkins M, "Subsequent primary neoplasms : risks, risk factors, surveillance, and future research", Pediatr Clin North Am, 67(6), pp.1135~1154 (2020)
35. Mei X, "Risk and outcome of subsequent malignancies after radioactive iodine treatment in differentiated thyroid cancer patients", BMC Cancer, 21(1), pp.543~ (2021)
36. Reinecke MJ, "Second primary malignancies induced by radioactive iodine treatment of differentiated thyroid carcinoma-a critical review and evaluation of the existing evidence", Eur J Nucl Med Mol Imaging, 49(9), pp.3247~3256 (2022)
37. Seo GH, "Increased risk of leukemia after radioactive iodine therapy in patients with thyroid cancer : a nationwide, population-based study in Korea", Thyroid, 25(8), pp.927~934 (2015)
38. Kitahara CM, "Association of radioactive iodine, antithyroid drug, and surgical treatments with solid cancer mortality in patients with hyperthyroidism", JAMA Netw Open, 3(7), pp.e209660~ (2020)
39. Cho YY, "Elevated risks of subsequent primary malignancies in patients with thyroid cancer : a nationwide, population-based study in Korea", Cancer, 121(2), pp.259~268 (2015)
40. Ahn HY, "Radioactive iodine therapy did not significantly increase the incidence and recurrence of subsequent breast cancer", J Clin Endocrinol Metab, 100(9), pp.3486~3493 (2015)
41. Iyer NG, "Rising incidence of second cancers in patients with low-risk(T1N0)thyroid cancer who receive radioactive iodine therapy", Cancer, 117(19), pp.4439~4446 (2011)
42. Kim C, "The risk of second cancers after diagnosis of primary thyroid cancer is elevated in thyroid microcarcinomas", Thyroid, 23(5), pp.575~582 (2013)
43. Ko KY, "(131)I treatment for thyroid cancer and the risk of developing salivary and lacrimal gland dysfunction and a second primary malignancy : a nationwide population-based cohort study", Eur J Nucl Med Mol Imaging, 42(8), pp.1172~1178 (2015)
44. Fallahi B, "Incidence of second primary malignancies during a long-term surveillance of patients with differentiated thyroid carcinoma in relation to radioiodine treatment", Clin Nucl Med, 36(4), pp.277~282 (2011)
45. Lang BH, "Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy", Surgery, 151(6), pp.844~850 (2012)
46. Molenaar RJ, "Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine", Leukemia, 32(4), pp.952~959 (2018)
47. Tulchinsky M, "Well-founded recommendations for radioactive iodine treatment of differentiated thyroid cancer require balanced study of benefits and harms", J Clin Oncol, 36(18), pp.1887~1888 (2018)
48. Verburg FA, "I-131 as adjuvant treatment for differentiated thyroid carcinoma may cause an increase in the incidence of secondary haematological malignancies : an"inconvenient"truth?", Eur J Nucl Med Mol Imaging, 45(13), pp.2247~2249 (2018)
49. Sadetzki S, "Childhood exposure to external ionising radiation and solid cancer risk", Br J Cancer, 100(7), pp.1021~1025 (2009)
50. Seo GH, "Radioactive iodine treatment for children and young adults with thyroid cancer in South Korea : a population-based study", J Clin Endocrinol Metab, 106(7), pp.e2580~e2588 (2021)
51. Kim S, "Second primary malignancy risk in thyroid cancer and matched patients with and without radioiodine therapy analysis from the observational health data sciences and informatics", Eur J Nucl Med Mol Imaging, 49(10), pp.3547~3556 (2022)
52. Busque L, "Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis", Nat Genet, 44(11), pp.1179~1181 (2012)
53. Genovese G, "Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence", N Engl J Med, 371(26), pp.2477~2487 (2014)
54. Gibson CJ, "Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma", J Clin Oncol, 35(14), pp.1598~1605 (2017)
55. Gulec SA, "A joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on current diagnostic and theranostic approaches in the management of thyroid cancer", Thyroid, 31(7), pp.1009~1019 (2021)
56. Lassmann M, "EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I : blood and bone marrow dosimetry in differentiated thyroid cancer therapy", Eur J Nucl Med Mol Imaging, 35(7), pp.1405~1412 (2008)
57. Stokke C, "Dosimetry-based treatment planning for molecular radiotherapy : a summary of the 2017 report from the Internal Dosimetry Task Force", EJNMMI Phys, 4(1), pp.27~ (2017)
58. Yang Z, "Comparison of survival outcomes following postsurgical radioactive iodine versus external beam radiation in stage IV differentiated thyroid carcinoma", Thyroid, 27(7), pp.944~952 (2017)
59. Goldman MB, "Radioactive iodine therapy and breast cancer. a follow-up study of hyperthyroid women", Am J Epidemiol, 127(5), pp.969~980 (1988)
60. Holm LE, "Cancer risk after iodine-131 therapy for hyperthyroidism", J Natl Cancer Inst, 83(15), pp.1072~1077 (1991)
61. Saenger EL, "Incidence of leukemia following treatment of hyperthyroidism. Preliminary report of the cooperative thyrotoxicosis therapy follow-up study", JAMA, 205(12), pp.855~862 (1968)
62. Dobyns BM, "Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism : a report of the cooperative thyrotoxicosis therapy follow-up study", J Clin Endocrinol Metab, 38(6), pp.976~998 (1974)
63. Ron E, "Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group", JAMA, 280(4), pp.347~355 (1998)
64. Taylor PN, "Joint statement from the Society for Endocrinology and the British Thyroid Association regarding 'Association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism'", Clin Endocrinol(Oxf), 92(3), pp.266~267 (2020)
65. Anderson C, "Trends in the proportion of second or later primaries among all newly diagnosed malignant cancers", Cancer, 127(15), pp.2736~2742 (2021)
66. Kazumasa Shimada, "Lifetime Risk Assessment of Lung Cancer Incidence for Nonsmokers in Japan Considering the Joint Effect of Radiation and Smoking Based on the Life Span Study of Atomic Bomb Survivors", 방사선방어학회지, 46(3), pp.83~97 (2021), 테스트학회

관련 논문AI추천